Amarin (AMRN) Competitors $0.46 -0.01 (-1.18%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMRN vs. KROS, TYRA, ERAS, CRON, EOLS, DNTH, RAPP, AUTL, CGEM, and OCSShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Cullinan Therapeutics Oculis Keros Therapeutics (NASDAQ:KROS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Is KROS or AMRN more profitable? Amarin has a net margin of -16.33% compared to Keros Therapeutics' net margin of -27,890.94%. Amarin's return on equity of -7.22% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics-27,890.94% -41.74% -38.42% Amarin -16.33%-7.22%-4.96% Does the MarketBeat Community believe in KROS or AMRN? Amarin received 787 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 74.10% of users gave Amarin an outperform vote while only 70.37% of users gave Keros Therapeutics an outperform vote. CompanyUnderperformOutperformKeros TherapeuticsOutperform Votes5770.37% Underperform Votes2429.63% AmarinOutperform Votes84474.10% Underperform Votes29525.90% Which has preferable valuation and earnings, KROS or AMRN? Amarin has higher revenue and earnings than Keros Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$651K1,059.65-$152.99M-$5.21-3.27Amarin$241.02M0.78-$59.11M-$0.09-5.11 Do institutionals and insiders hold more shares of KROS or AMRN? 71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by insiders. Comparatively, 2.0% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor KROS or AMRN? In the previous week, Keros Therapeutics had 20 more articles in the media than Amarin. MarketBeat recorded 22 mentions for Keros Therapeutics and 2 mentions for Amarin. Keros Therapeutics' average media sentiment score of 0.05 beat Amarin's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, KROS or AMRN? Keros Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Amarin has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Do analysts rate KROS or AMRN? Keros Therapeutics presently has a consensus price target of $81.33, suggesting a potential upside of 377.59%. Given Keros Therapeutics' higher possible upside, equities analysts plainly believe Keros Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.71Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAmarin beats Keros Therapeutics on 10 of the 18 factors compared between the two stocks. Ad ProsperityPubWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.91M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-5.1110.5991.3417.19Price / Sales0.78195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book0.345.104.794.78Net Income-$59.11M$151.51M$120.07M$225.60M7 Day Performance1.03%-2.15%-1.90%-1.23%1 Month Performance-12.36%-3.14%11.45%3.37%1 Year Performance-48.31%11.50%30.63%16.58% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.0331 of 5 stars$0.46-1.2%N/A-42.6%$188.91M$241.02M-5.11360Analyst ForecastKROSKeros Therapeutics3.2961 of 5 stars$18.88+0.3%$81.33+330.8%-49.6%$764.77M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0741 of 5 stars$14.90-0.3%$31.00+108.1%+2.0%$753.94MN/A-9.2820Positive NewsERASErasca2.17 of 5 stars$2.62+2.3%$5.90+125.2%+35.8%$740.75MN/A-3.08126News CoveragePositive NewsGap UpCRONCronos Group1.8449 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageEOLSEvolus3.8301 of 5 stars$11.51flat$23.00+99.8%+12.5%$728.81M$202.09M-12.73170DNTHDianthus Therapeutics1.3413 of 5 stars$24.31+2.1%$46.43+91.0%+213.2%$719.58M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5264 of 5 stars$19.34+3.0%$35.00+81.0%N/A$707.46MN/A0.00N/AAUTLAutolus Therapeutics2.5563 of 5 stars$2.63+5.6%$10.40+295.4%-58.4%$699.82M$1.70M-2.06330CGEMCullinan Therapeutics1.8004 of 5 stars$11.90+1.3%$31.67+166.1%+32.7%$692.91M$18.94M-4.1430News CoverageOCSOculis1.6453 of 5 stars$17.06-0.2%$29.20+71.2%+57.2%$691.00M$980,000.00-8.852 Related Companies and Tools Related Companies Keros Therapeutics Alternatives Tyra Biosciences Alternatives Erasca Alternatives Cronos Group Alternatives Evolus Alternatives Dianthus Therapeutics Alternatives Rapport Therapeutics Alternatives Autolus Therapeutics Alternatives Cullinan Therapeutics Alternatives Oculis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts